Blood cancer transplant study aims to reduce dangerous side effects
NCT ID NCT03555851
First seen Jan 08, 2026
Summary
This study is for adults with blood cancers like leukemia who are getting a stem cell transplant. Researchers want to learn how a person's genes and the amount of a drug called cyclophosphamide in their blood affect the risk of graft-versus-host disease (GVHD), a serious side effect. The goal is to find better ways to prevent GVHD while keeping the transplant's cancer-fighting benefits. About 120 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.